Robyn Cunard, M.D.
I have focused my work on the immunologic effects of peroxisome proliferator-activated receptors (PPARs) and their ligands. PPAR ligands are used to treat hyperlipidemia and type 2 diabetes, however our studies and those of others have shown that these agents are also immunosuppressive. We use animal models of inflammatory disease, including multiple sclerosis and experimental glomerulonephritis to study the effects of PPAR ligands on these inflammatory diseases. We also utilize extensive molecular biological techniques to study whether PPAR ligands are immunomodulatory.
Cunard R, Ricote M, DiCampli D, Archer DC, Kahn DA, Glass, CK and Kelly CJ. Regulation of cytokine expression by ligands of peroxisome-proliferator activated receptors. J Immunol, 168:2795-2802, 2002.
Cunard R and DiCampli DJ (co-first authors), Archer DC, Stevenson J, and Kelly CJ. WY14,643 is a profound immunosuppressive agent in vivo. J Immunol, 169:6806-6812, 2002.
Cunard R, Eto Y, Muljadi JT, Glass CK, Kelly CJ and Ricote M. Repression of Interferon-gamma expression by PPARg. J. of Immunol. 172: 7530-6, 2004.
Selim, E, Frkanec, J, Cunard R. Fibrates upregulate TRB3 in lymphocytes independent of PPARa by augmenting CCAAT/Enhancer-binding proteinb (C/EBPb) expression. Mol. Immunol. 44: 1218-29, 2007.
Sampogna, R and Cunard, R. Roundupä Intoxication and Rationale for Treatment. In Press. Clin. Neph, 2007.
Archer DC, Frkanec, JT, Cromwell, J. Clopton, P, and Cunard, R, WY14,643, a PPARa ligand attenuates expression of anti-glomerular basement membrane disease. In Review: Clin Exp Imm. 2007.